Latest Manufacturing News

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

archTIS delivered a 231% year-on-year increase in annual recurring revenue to A$15.1 million, marked by the full deployment of its US Department of Defense custom software and a significant contract with a US-European military alliance.

Firebird Metals has locked in a purpose-built industrial facility in Osborne Park, Perth, to house its pioneering Australian Demonstration Plant, the only fully integrated manganese concentrate-to-cathode active material facility outside China.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

Prairie Lithium has moved Pad #1 from groundwork to active building construction, backed by SaskPower's powerline installation and a binding Hydro Lithium offtake agreement that includes a A$10 million equipment contribution. First production is targeted for Q4 2026.

Alpha HPA Limited reports robust progress on its HPA First Project Stage 2, backed by a $225 million capital raise, while securing significant demand upgrades from Japanese semiconductor customers.

Zimi Limited posted 14% revenue growth and landed its biggest project order to date with Homecorp, while slashing operating costs and launching an AI sales agent.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.